{"job_id": "9973015c-facf-420e-a3a8-ce96d72dc5f1", "brochure_id": "9973015c-facf-420e-a3a8-ce96d72dc5f1", "brochure_name": "BTM Brochure_22 Sept.pdf", "status": "completed", "results": [{"statement": "Epidemiology. 2.3 million new breast cancer cases were diagnosed globally in 2022, with 42.9% of them in Asia.\u00b9", "reference_no": "1", "reference": "Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2024. Accessed May 21, 2025. https://gco.iarc.fr/today", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1.Ferlay J,2025.pdf: Asia 985 817 42.9%", "validation_result": "Supported", "page_location": "Page 1, under Incidence pie chart", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Epidemiology. the Asia-Pacific (APAC) region recorded 985,400 new cases, and 315,100 deaths in 2022, predicted to reach 1.4 million cases by 2050.3", "reference_no": "3", "reference": "Fu M, Peng Z, Wu M, Lv D, Li Y, Lyu S. Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050. The Breast. 2025;79:103835. doi:https://doi.org/10.1016/ j.breast.2024.103835", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 3.Fu M,2024.pdf: In Asia, an estimated 985.4 thousand new cases and 315.1 thousand deaths were reported, corresponding to age-standardized incidence and mortality rates of 34.3 and 10.5 per 100,000, respectively.|China and India are the leading contributors to both new cases and deaths, with projections indicating that by 2050, around 1.4 million new breast cancer cases and 0.5 million deaths are expected to occur in Asia.", "validation_result": "Supported", "page_location": "Page 2, Results section", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Epidemiology. Asian women are diagnosed at younger ages (median 40-50 yrs.) compared to Western women (60-70 yrs.).\u00b2", "reference_no": "2", "reference": "Lim YX, Lim ZL, Ho PJ, Li J. Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives. Cancers (Basel). 2022 Aug30;14(17):4218.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Lim YX, 2022.pdf: Breast cancer strikes Asian women earlier than it does Western women [2,3].|In Asian countries, the peak age is between 40 and 50 years, while in Western countries, it is between 60 and 70 years [2,3].", "validation_result": "Supported", "page_location": "Page 2, Section 1.2", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Epidemiology. Breast cancer in young women is often more aggressive with a high recurrence risk, requiring regular follow-ups.\u2075", "reference_no": "5", "reference": "Beadle BM, Woodward WA, Buchholz TA. The Impact of Age on Outcome in Early-Stage Breast Cancer. Seminars in Radiation Oncology. 2011;21(1):26-34. doi:https://doi.org/10.1016/j.semradonc.2010.09.001", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 5.Beadle BM,2011.pdf: Numerous studies have shown very different breast cancer outcomes based on patient age; younger women typically have more aggressive tumors that are more likely to recur both locoregionally and distantly, and older women more commonly have less aggressive disease.", "validation_result": "Supported", "page_location": "Page 1, Abstract", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Recent Trends in Breast Cancer Management. NAC, administered before surgery to shrink tumors, has become a key approach in the management of locally advanced breast cancer. 6 Increasingly, NAC is also used in early-stage breast cancer to:7", "reference_no": "6,7", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 7.P Y Christina,2024.pdf: The advent of neoadjuvant chemotherapy (NAC) has revolutionized the treatment paradigm for locally advanced breast cancer.", "validation_result": "Supported", "page_location": "Page 2, Introduction", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Recent Trends in Breast Cancer Management. NAC, administered before surgery to shrink tumors, has become a key approach in the management of locally advanced breast cancer. 6 Increasingly, NAC is also used in early-stage breast cancer to:7", "reference_no": "6,7", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 7.P Y Christina,2024.pdf: The advent of neoadjuvant chemotherapy (NAC) has revolutionized the treatment paradigm for locally advanced breast cancer.", "validation_result": "Supported", "page_location": "Page 2, Introduction", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. Precise localization of small lesions remains a challenge for biopsy or for follow up.8", "reference_no": "6,8", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: tissue markers allow for rapid confirmation of correct target excision at\nthe time of surgery and can guide pathologists to the area of interest\nwithin a mastectomy specimen [8].\n- 8.Martin ,2022.pdf: Breast marker enables physicians to efficiently identify and pinpoint tissues that have already been suspected and ana- lyzed for the possibility of cancer [16].", "validation_result": "Supported", "page_location": "Page 1, Introduction | Page 3, Section 2.3 Localization for surgery", "confidence_score": 0.84, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. Precise localization of small lesions remains a challenge for biopsy or for follow up.8", "reference_no": "6,8", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: tissue markers allow for rapid confirmation of correct target excision at\nthe time of surgery and can guide pathologists to the area of interest\nwithin a mastectomy specimen [8].\n- 8.Martin ,2022.pdf: Breast marker enables physicians to efficiently identify and pinpoint tissues that have already been suspected and ana- lyzed for the possibility of cancer [16].", "validation_result": "Supported", "page_location": "Page 1, Introduction | Page 3, Section 2.3 Localization for surgery", "confidence_score": 0.84, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. When multiple lesions are detected on one side of the breast, it becomes challenging to differentiate one from another.6", "reference_no": "6", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: When multiple lesions are found in a single breast in a patient with a known cancer, placement of uniquely shaped tissue markers at each site allows for assessment of extent of disease and differentiation between benign and malignant sites.", "validation_result": "Supported", "page_location": "Page 3, Section 2.3 Extent of disease assessment", "confidence_score": 0.89, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. Mismatches between imaging modalities can lead to missed diagnoses or repeat biopsies.6", "reference_no": "6", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: Furthermore, tissue\nmarker placement has proven extremely useful in assessing extent of\ndisease when more than one site is biopsied, allowing for correlation\nbetween modalities, preventing repeat biopsies of benign lesions, and\nallowing for accurate localization following neoadjuvant chemotherapy\n[6, 7].", "validation_result": "Supported", "page_location": "Page 1, Introduction", "confidence_score": 0.89, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. NAC often reduces tumors to small, deep, non-palpable lesions, making precise localization difficult during surgery.6.7", "reference_no": "6,7", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: In the setting of neoadjuvant chemotherapy, tumors may significantly decrease in size and may become occult on imaging. |In patients who opt for breast conservation therapy, the clip placed at time of initial biopsy may serve as the only reliable landmark for pre-operative localization [15, 16].", "validation_result": "Supported", "page_location": "Page 3, Section 2.4 Neoadjuvant chemotherapy", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Unmet Challenges in Modern Breast Cancer Management. NAC often reduces tumors to small, deep, non-palpable lesions, making precise localization difficult during surgery.6.7", "reference_no": "6,7", "reference": "Shah AD, Mehta AK, Talati N, Brem R, Margolies LR. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 6.Shah A, 2018.pdf: In the setting of neoadjuvant chemotherapy, tumors may significantly decrease in size and may become occult on imaging. |In patients who opt for breast conservation therapy, the clip placed at time of initial biopsy may serve as the only reliable landmark for pre-operative localization [15, 16].", "validation_result": "Supported", "page_location": "Page 3, Section 2.4 Neoadjuvant chemotherapy", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Breast Tissue Markers: A Key to Precision in Cancer Care. A breast biopsy marker is a small, surgical-grade device placed at the biopsy site under image guidance. It enables clear identification and visualization of abnormal breast tissue, axillary lesions, and lymph nodes, ensuring accurate clinical follow-up and treatment planning.8", "reference_no": "8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 8.Martin ,2022.pdf: Breast biopsy marker enables identification and visualization of abnormal breast tissue, breast and axilla legions, and lymph nodes under clinical follow-up care.", "validation_result": "Supported", "page_location": "Page 3, Article highlights", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Overcoming Challenges in Detection and Treatment. Ensures precise marking of biopsy sites to aid future imaging and interventions, while differentiating new from previously biopsied tissue and preventing repeat biopsies. 8.9", "reference_no": "8,9", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: The placement of a breast marker following a biopsy or to mark an abnormality in the breast has become standard practice in the clinical setting. | Breast biopsy markers offer a wide range of benefits which includes the prevention of re-biopsy of a benign tumor, differentiating multiple lesions within the breast, evaluation of the extent of a tumor, and increased precision during surgery.", "validation_result": "Supported", "page_location": "Page 2, Abstract", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Overcoming Challenges in Detection and Treatment. Ensures precise marking of biopsy sites to aid future imaging and interventions, while differentiating new from previously biopsied tissue and preventing repeat biopsies. 8.9", "reference_no": "8,9", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: The placement of a breast marker following a biopsy or to mark an abnormality in the breast has become standard practice in the clinical setting. | Breast biopsy markers offer a wide range of benefits which includes the prevention of re-biopsy of a benign tumor, differentiating multiple lesions within the breast, evaluation of the extent of a tumor, and increased precision during surgery.", "validation_result": "Supported", "page_location": "Page 2, Abstract", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Overcoming Challenges in Detection and Treatment. Increases the chances of achieving clear lesion margins (90% with markers vs. 31-62% without), ensuring targeted excision.", "reference_no": "8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 8.Martin ,2022.pdf: For example, during breast surgery, 90% clear lesion margins are achieved when utilizing breast biopsy markers, while only 31-62% clear margins are achieved without a breast marker [3,7-9].", "validation_result": "Supported", "page_location": "Page 2, Introduction", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Overcoming Challenges in Detection and Treatment. Easily identifiable through ultrasound (US), stereotactic (S), mammographic, and MRI guidance for accurate positioning.8", "reference_no": "8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 8.Martin ,2022.pdf: Breast biopsy markers are easy to recognize and pinpoint by stereotactic (S) and ultrasound (US) guidance, mammogram, and magnetic resonance imaging (MRI) techniques [6].", "validation_result": "Supported", "page_location": "Page 2, paragraph 5", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Overcoming Challenges in Detection and Treatment. Facilitates multifocal tumor assessment, accurate tissue sampling, and precise marker placement during chemotherapy.8", "reference_no": "8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 8.Martin ,2022.pdf: Breast markers are also convenient when assessing the multifocality of a tumor if multiple sites of the breast have been biopsied, and in modality correlation, minimizing repeated biopsies, and in precise marker placement at the beginning and during chemotherapy [3,4].", "validation_result": "Supported", "page_location": "Page 2, Introduction", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Practical Applications of Breast Tissue Markers. Practical Applications of Breast Tissue Markers 8,10", "reference_no": "10,8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: N/A\n- 10.Thomassin-naggara2011.pdf: None", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "LOW"}, {"statement": "Practical Applications of Breast Tissue Markers. Practical Applications of Breast Tissue Markers 8,10", "reference_no": "10,8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: N/A\n- 10.Thomassin-naggara2011.pdf: None", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "LOW"}, {"statement": "Post-Biopsy Localization. Post-Biopsy Localization 10,11", "reference_no": "10,11", "reference": "Thomassin-Naggara I, Lalonde L, David J, Darai E, Uzan S, Trop I. A plea for the biopsy marker: how, why and why not clipping after breast biopsy?. Breast Cancer Res Treat. 2012;132(3):881-893.11. Nurko J, Mancino AT, Whitacre E, Edwards MJ. Surgical bene\ufb01ts conveyed by biopsy site marking system using ultrasound localization. Am J Surg. 2005;190(4):618-622.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 10.Thomassin-naggara2011.pdf: Biopsy clips can be deployed after all percutaneous biopsies, and we present below the arguments to support this statement.\n- 11.Nurko, 2005.pdf: Background: With vacuum-assisted biopsy technology all, or most, of a breast lesion may be removed during the initial biopsy; in such cases a metallic marker is often inserted at the site of the biopsy for future localization.", "validation_result": "Supported", "page_location": "Page 2, paragraph starting with \"Biopsy clips can be deployed...\" | Abstract", "confidence_score": 0.97, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Post-Biopsy Localization. Post-Biopsy Localization 10,11", "reference_no": "10,11", "reference": "Thomassin-Naggara I, Lalonde L, David J, Darai E, Uzan S, Trop I. A plea for the biopsy marker: how, why and why not clipping after breast biopsy?. Breast Cancer Res Treat. 2012;132(3):881-893.11. Nurko J, Mancino AT, Whitacre E, Edwards MJ. Surgical bene\ufb01ts conveyed by biopsy site marking system using ultrasound localization. Am J Surg. 2005;190(4):618-622.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 10.Thomassin-naggara2011.pdf: Biopsy clips can be deployed after all percutaneous biopsies, and we present below the arguments to support this statement.\n- 11.Nurko, 2005.pdf: Background: With vacuum-assisted biopsy technology all, or most, of a breast lesion may be removed during the initial biopsy; in such cases a metallic marker is often inserted at the site of the biopsy for future localization.", "validation_result": "Supported", "page_location": "Page 2, paragraph starting with \"Biopsy clips can be deployed...\" | Abstract", "confidence_score": 0.97, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "US-Guided Axillary Node Localization Post-NAC. US-Guided Axillary Node Localization Post-NAC12", "reference_no": "12", "reference": "Kim KE, Ko EY, Han BK, et al. Comparison of the Ultrasound Visibility of Tissue Markers in Metastatic Lymph Nodes after Neoadjuvant Chemotherapy in Patients with Breast Cancer. Diagnostics (Basel). 2022;12(10):2424.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 12. Kim KE,2022.pdf: Various methods of preoperative localization for clipped lymph nodes\u2014including iodine-125 radioactive seeds, ultrasound (US)-guided wire localization, and tattooing\u2014are performed after NAC.|However, US-guided localization of axillary lymph nodes after a partial or complete radiologic response to neoadjuvant chemotherapy may often be challenging to radiologists [12,13].", "validation_result": "Supported", "page_location": "Page 2, Introduction", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "US-Guided Axillary Node Localization Post-NAC. A study documented that breast biopsy clips and point markers enabled 90% tailored axillary surgery (TAS) success with 0% false negatives, ensuring precise lymph node removal. 13", "reference_no": "13", "reference": "Endo Y, Kotani H, Tamura N, et al. Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer. 2024;31(6):1130-1136.14. AGuidelines Detail. NCCN. Published 2020. Accessed May 21, 2025. https://www.nccn.org/guidelines/guidelines-detail?id=1419.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 13. Endo,2024.pdf: TAS was successful in 18 of the 20 patients (90%) (Table 3 and Fig. 1).|Seven patients underwent TAS and axillary lymph node dissection with a false-negative rate of 0%.", "validation_result": "Supported", "page_location": "Abstract, Results (page 1, 3)", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Other indications. Other indications 8,10", "reference_no": "10,8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: [No evidence text provided]\n- 10.Thomassin-naggara2011.pdf: None", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "LOW"}, {"statement": "Other indications. Other indications 8,10", "reference_no": "10,8", "reference": "Martin EA,Chauhan N, Dhevan V, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.9. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and Challenges of Using Breast Biopsy Markers. J Breast Imaging. 2022;4(1):78-95.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 8.Martin ,2022.pdf: [No evidence text provided]\n- 10.Thomassin-naggara2011.pdf: None", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "LOW"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. National Comprehensive Cancer Network 14", "reference_no": "14", "reference": "", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 14.NCCN breast cancer,2024.pdf: None", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. American Cancer Society 15", "reference_no": "15", "reference": "American Cancer Society. Core Needle Biopsy of the Breast | Stereotactic Breast Biopsy. www.cancer.org. Published 2022. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-biopsy/core-needle-biopsy-of-the-breast.html", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 15.American Cancer Society. 2022.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. American Society of Breast Surgeons 16", "reference_no": "16", "reference": "Image-Guided Percutaneous Biopsy of Palpable and Nonpalpable Breast Lesions. https://breastsurgeons.org/docs/statements/Consensus-Guideline-on-Image-Guided-Percutaneous-Biopsy-of-Palpable-and-Nonpalpable -Breast-Lesions.pdf", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 16.Image-Guided Percutaneous.pdf: American Society of Breast Surgeons. Position statement on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions.", "validation_result": "Supported", "page_location": "References, page 5, reference 16", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. Canadian Cancer Society 17", "reference_no": "17", "reference": "Cancer C. Stereotactic core biopsy. Canadian Cancer Society. Published 2015. https://cancer.ca/en/treatments/ tests-and- procedures/stereotactic-core-biopsy.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 17.Cancer C,2015.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. European Commission Initiative on Breast Cancer 18", "reference_no": "18", "reference": "European guidelines on breast cancer screening and diagnosis | European Commission Initiative on Breast and Colorectal cancer. cancer-screening-and-care.jrc.ec.europa.eu. https://cancer-screening -and-care.jrc.ec.europa.eu/en/ecibc/european-breast-cancer-guidelines", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18.European guidelines on breast cancer screening and diagnosis.pdf: None", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. European Society of Medical Oncology 19", "reference_no": "19", "reference": "Loibl S, Varga A, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020. Annals of Oncology. 2023;35(2).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 19.Loibl S, 2023.pdf: annonc.2023.11.016, and are also described in the Euro-\npean Society for Medical Oncology (ESMO) Clinical Practice\nGuideline (CPG) for risk reduction and screening of cancer in\nhereditary breast-ovarian cancer syndromes.4", "validation_result": "Supported", "page_location": "Page 2, Diagnosis and Imaging section", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. Cancer Australia 20", "reference_no": "20", "reference": "Interpretation of the evidence. Cancer Australia. Published 2017.15. https://www.canceraustralia.gov.au/resources/position-statements/ position-statement-use-\ufb01ne- needle-aspiration- and-core- biopsy-breastbreastscreen-australia-program/interpretation -evidence.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 20.Interpretation of the evidence..pdf: The search for Australian clinical guidance identified two documents. One was developed by BreastScreen Australia Clinical Advisory Committee (CAC) (BreastScreen Australia 2017) and the other by Cancer Australia, Investigation of a new breast symptom: a guide for General Practitioners (INBS) (Cancer Australia 2017).", "validation_result": "Supported", "page_location": "Page 6, paragraph 2", "confidence_score": 0.94, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Guideline Recommendations for Breast Tissue Markers. Breast Imaging Society of India21", "reference_no": "21", "reference": "Suma Chakrabarthi, Shikha Panwar, Singh T, et al. Best Practice Guidelines for Breast Imaging, Breast Imaging Society, India: Part\u20142. Annals of the National Academy of Medical Sciences (India). 2022;58(02):069-077 Abbreviations: APAC - Asia-Paci\ufb01c; NAC - Neoadjuvant Chemotherapy; BCS - Breast-Conserving Surgery; MRI - Magnetic Resonance Imaging; US - Ultrasound; MG - Mammography; LN - Lymph Node; TAS - Tailored Axillary Surgery; BRCA - Breast Cancer; FNA - Fine Needle Aspiration; NCB - Needle Core Biopsy; VANCB - Vacuum-Assisted Needle Core Biopsy; USA - United States of America", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 21.Suma Chakrabarthi,2022.pdf: These guidelines framed by the task group set up by the Breast Imaging Society, India, have been formulated focusing primarily on the Indian patients and health care infrastructures.", "validation_result": "Supported", "page_location": "Abstract", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}], "created_at": "2026-02-03T06:16:37.467661"}